Unequal risks for breast cancer associated with different hormone replacement therapies: Results from the E3N cohort study

Agnès Fournier, Franco Berrino, Françoise Clavel-Chapelon

Research output: Contribution to journalArticle

Abstract

Large numbers of hormone replacement therapies (HRTs) are available for the treatment of menopausal symptoms. It is still unclear whether some are more deleterious than others regarding breast cancer risk. The goal of this study was to assess and compare the association between different HRTs and breast cancer risk, using data from the French E3N cohort study. Invasive breast cancer cases were identified through biennial self-administered questionnaires completed from 1990 to 2002. During follow-up (mean duration 8.1 postmenopausal years), 2,354 cases of invasive breast cancer occurred among 80,377 postmenopausal women. Compared with HRT never-use, use of estrogen alone was associated with a significant 1.29-fold increased risk (95% confidence interval 1.02-1.65). The association of estrogen-progestagen combinations with breast cancer risk varied significantly according to the type of progestagen: the relative risk was 1.00 (0.83-1.22) for estrogen-progesterone, 1.16 (0.94-1.43) for estrogen- dydrogesterone, and 1.69 (1.50-1.91) for estrogen combined with other progestagens. This latter category involves progestins with different physiologic activities (androgenic, nonandrogenic, antiandrogenic), but their associations with breast cancer risk did not differ significantly from one another. This study found no evidence of an association with risk according to the route of estrogen administration (oral or transdermal/percutaneous). These findings suggest that the choice of the progestagen component in combined HRT is of importance regarding breast cancer risk; it could be preferable to use progesterone or dydrogesterone.

Original languageEnglish
Pages (from-to)103-111
Number of pages9
JournalBreast Cancer Research and Treatment
Volume107
Issue number1
DOIs
Publication statusPublished - Jan 2008

Fingerprint

Hormone Replacement Therapy
Cohort Studies
Breast Neoplasms
Progestins
Estrogens
Dydrogesterone
Progesterone
Cutaneous Administration
Oral Administration
Confidence Intervals

Keywords

  • Breast cancer
  • Cohort
  • Dydrogesterone
  • Estrogen
  • Hormone replacement therapy
  • Menopause
  • Progestagens
  • Progesterone

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Unequal risks for breast cancer associated with different hormone replacement therapies : Results from the E3N cohort study. / Fournier, Agnès; Berrino, Franco; Clavel-Chapelon, Françoise.

In: Breast Cancer Research and Treatment, Vol. 107, No. 1, 01.2008, p. 103-111.

Research output: Contribution to journalArticle

Fournier, Agnès ; Berrino, Franco ; Clavel-Chapelon, Françoise. / Unequal risks for breast cancer associated with different hormone replacement therapies : Results from the E3N cohort study. In: Breast Cancer Research and Treatment. 2008 ; Vol. 107, No. 1. pp. 103-111.
@article{c5c270d0a2bb47e7855fd171d785f565,
title = "Unequal risks for breast cancer associated with different hormone replacement therapies: Results from the E3N cohort study",
abstract = "Large numbers of hormone replacement therapies (HRTs) are available for the treatment of menopausal symptoms. It is still unclear whether some are more deleterious than others regarding breast cancer risk. The goal of this study was to assess and compare the association between different HRTs and breast cancer risk, using data from the French E3N cohort study. Invasive breast cancer cases were identified through biennial self-administered questionnaires completed from 1990 to 2002. During follow-up (mean duration 8.1 postmenopausal years), 2,354 cases of invasive breast cancer occurred among 80,377 postmenopausal women. Compared with HRT never-use, use of estrogen alone was associated with a significant 1.29-fold increased risk (95{\%} confidence interval 1.02-1.65). The association of estrogen-progestagen combinations with breast cancer risk varied significantly according to the type of progestagen: the relative risk was 1.00 (0.83-1.22) for estrogen-progesterone, 1.16 (0.94-1.43) for estrogen- dydrogesterone, and 1.69 (1.50-1.91) for estrogen combined with other progestagens. This latter category involves progestins with different physiologic activities (androgenic, nonandrogenic, antiandrogenic), but their associations with breast cancer risk did not differ significantly from one another. This study found no evidence of an association with risk according to the route of estrogen administration (oral or transdermal/percutaneous). These findings suggest that the choice of the progestagen component in combined HRT is of importance regarding breast cancer risk; it could be preferable to use progesterone or dydrogesterone.",
keywords = "Breast cancer, Cohort, Dydrogesterone, Estrogen, Hormone replacement therapy, Menopause, Progestagens, Progesterone",
author = "Agn{\`e}s Fournier and Franco Berrino and Fran{\cc}oise Clavel-Chapelon",
year = "2008",
month = "1",
doi = "10.1007/s10549-007-9523-x",
language = "English",
volume = "107",
pages = "103--111",
journal = "Breast Cancer Research and Treatment",
issn = "0167-6806",
publisher = "Springer New York LLC",
number = "1",

}

TY - JOUR

T1 - Unequal risks for breast cancer associated with different hormone replacement therapies

T2 - Results from the E3N cohort study

AU - Fournier, Agnès

AU - Berrino, Franco

AU - Clavel-Chapelon, Françoise

PY - 2008/1

Y1 - 2008/1

N2 - Large numbers of hormone replacement therapies (HRTs) are available for the treatment of menopausal symptoms. It is still unclear whether some are more deleterious than others regarding breast cancer risk. The goal of this study was to assess and compare the association between different HRTs and breast cancer risk, using data from the French E3N cohort study. Invasive breast cancer cases were identified through biennial self-administered questionnaires completed from 1990 to 2002. During follow-up (mean duration 8.1 postmenopausal years), 2,354 cases of invasive breast cancer occurred among 80,377 postmenopausal women. Compared with HRT never-use, use of estrogen alone was associated with a significant 1.29-fold increased risk (95% confidence interval 1.02-1.65). The association of estrogen-progestagen combinations with breast cancer risk varied significantly according to the type of progestagen: the relative risk was 1.00 (0.83-1.22) for estrogen-progesterone, 1.16 (0.94-1.43) for estrogen- dydrogesterone, and 1.69 (1.50-1.91) for estrogen combined with other progestagens. This latter category involves progestins with different physiologic activities (androgenic, nonandrogenic, antiandrogenic), but their associations with breast cancer risk did not differ significantly from one another. This study found no evidence of an association with risk according to the route of estrogen administration (oral or transdermal/percutaneous). These findings suggest that the choice of the progestagen component in combined HRT is of importance regarding breast cancer risk; it could be preferable to use progesterone or dydrogesterone.

AB - Large numbers of hormone replacement therapies (HRTs) are available for the treatment of menopausal symptoms. It is still unclear whether some are more deleterious than others regarding breast cancer risk. The goal of this study was to assess and compare the association between different HRTs and breast cancer risk, using data from the French E3N cohort study. Invasive breast cancer cases were identified through biennial self-administered questionnaires completed from 1990 to 2002. During follow-up (mean duration 8.1 postmenopausal years), 2,354 cases of invasive breast cancer occurred among 80,377 postmenopausal women. Compared with HRT never-use, use of estrogen alone was associated with a significant 1.29-fold increased risk (95% confidence interval 1.02-1.65). The association of estrogen-progestagen combinations with breast cancer risk varied significantly according to the type of progestagen: the relative risk was 1.00 (0.83-1.22) for estrogen-progesterone, 1.16 (0.94-1.43) for estrogen- dydrogesterone, and 1.69 (1.50-1.91) for estrogen combined with other progestagens. This latter category involves progestins with different physiologic activities (androgenic, nonandrogenic, antiandrogenic), but their associations with breast cancer risk did not differ significantly from one another. This study found no evidence of an association with risk according to the route of estrogen administration (oral or transdermal/percutaneous). These findings suggest that the choice of the progestagen component in combined HRT is of importance regarding breast cancer risk; it could be preferable to use progesterone or dydrogesterone.

KW - Breast cancer

KW - Cohort

KW - Dydrogesterone

KW - Estrogen

KW - Hormone replacement therapy

KW - Menopause

KW - Progestagens

KW - Progesterone

UR - http://www.scopus.com/inward/record.url?scp=36549076409&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=36549076409&partnerID=8YFLogxK

U2 - 10.1007/s10549-007-9523-x

DO - 10.1007/s10549-007-9523-x

M3 - Article

C2 - 17333341

AN - SCOPUS:36549076409

VL - 107

SP - 103

EP - 111

JO - Breast Cancer Research and Treatment

JF - Breast Cancer Research and Treatment

SN - 0167-6806

IS - 1

ER -